As of March 9, 2026, the long-predicted "reckoning" for American small-cap stocks has officially arrived. While the broader market remains buoyed by the resilient "Magnificent Seven" and a robust AI infrastructure supercycle, the Russell 2000 (IWM) has hit a formidable roadblock: a $1.35 trillion "debt maturity wall." After a
FDA refused approval for tabelecleucel in treating patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease earlier this year.
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its lead candidate, tabelecleucel (Ebvallo). The regulatory setback, which the
The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As investors aggressively rotate capital out of the overextended technology giants that dominated the previous three
The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that the Federal Reserve will remain hawkish well into the new year. While the blue-chip S&P 500 (INDEXSP: .INX) showed
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
